The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site
Authors:
- Sergei BoichukSergei Boichuk
- Aigul GalembikovaAGAigul Galembikova
- Kirill SyuzovKSKirill Syuzov
- Pavel DunaevPDPavel Dunaev
- Firuza BikinievaFBFiruza Bikinieva
- Aida AukhadievaAAAida Aukhadieva
- Svetlana ZykovaSZSvetlana Zykova
- Nazim IgidovNINazim Igidov
- Ksenia GankovaKGKsenia Gankova
- Maria NovikovaMNMaria Novikova
- Pavel KopninPavel Kopnin
Open Access
- 24 September 2021
- Vol. 26 (19) , 5780
Abstract
Microtubule targeting agents (MTAs) that interfere with the dynamic state of the mitotic spindle are well-known and effective chemotherapeutic agents. These agents interrupt the microtubule network via polymerization or depolymerization, halting the cell cycle progression and leading to apoptosis. We report two novel pyrrole-based carboxamides (CAs) (CA-61 and -84) as the compounds exhibiting potent anti-cancer properties against a broad spectrum of epithelial cancer cell lines, including breast, lung, and prostate cancer. The anti-cancer activity of CAs is due to their ability to interfere with the microtubules network and inhibit tubulin polymerization. Molecular docking demonstrated an efficient binding between these ligands and the colchicine-binding site on the tubulin. CA-61 formed two hydrogen bond interactions with THR 179 (B) and THR 353 (B), whereas two hydrogen bonds with LYS 254 (B) and 1 with ASN 101 (A) were identified for CA-84. The binding energy for CA-84 and CA-61 was −9.910 kcal/mol and −9.390 kcal/mol. A tubulin polymerization assay revealed a strong inhibition of tubulin polymerization induced by CA-61 and -84. The immunofluorescence data revealed the disruption of the tubulin assembly in CA-treated cancer cells. As an outcome of the tubulin inhibition, these compounds halted the cell cycle progression in the G2/M phase, leading to the accumulation of the mitotic cells, and further induced apoptosis. Lastly, the in vivo study indicated that CAs significantly inhibited the HCC1806 breast cancer xenograft tumor growth in a nude mouse model. Collectively, we identified the novel CAs as potent MTAs, inhibiting tubulin polymerization via binding to the colchicine-binding site, disrupting the microtubule network, and exhibiting potent pro-apoptotic activities against the epithelial cancer cell lines both in vitro and in vivo.Keywords
Funding Information
- Russian Science Foundation (20-15-0001)
This publication has 54 references indexed in Scilit:
- Chemistry of iminofuran: VIII. Recyclization of 5-aryl-3-arylimino-3H-furan-2-ones effected by cyanoacetic acid derivativesRussian Journal of Organic Chemistry, 2013
- Pyrrole-Based Antitubulin Agents: Two Distinct Binding Modalities Are Predicted for C-2 Analogues in the Colchicine SiteACS Medicinal Chemistry Letters, 2011
- The VSGB 2.0 model: A next generation energy model for high resolution protein structure modelingProteins: Structure, Function, and Bioinformatics, 2011
- Microtubule-binding agents: a dynamic field of cancer therapeuticsNature Reviews Drug Discovery, 2010
- ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor ActivityMolecular Cancer Therapeutics, 2010
- Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing MiceClinical Cancer Research, 2006
- ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agentCancer Cell, 2005
- Peloruside A: A Potent Cytotoxic Macrolide Isolated from the New Zealand Marine Sponge Mycale sp.The Journal of Organic Chemistry, 1999
- Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.Journal of Clinical Investigation, 1997
- Taxol: Mechanisms of Action and ResistanceaAnnals of the New York Academy of Sciences, 1986